Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 08/31
(Values in thousands)
| 05-2026 | 02-2026 | 11-2025 | 08-2025 | 05-2025 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 19 | 19 | 17 | 21 | 31 |
| Accounts receivable | -7 | 46 | 280 | -10 | -27 |
| Other Working Capital | 237 | -814 | 490 | -324 | -344 |
| Other Operating Activity | -1,884 | -1,415 | -1,772 | -2,330 | -3,244 |
| Operating Cash Flow | $-1,635 | $-2,164 | $-984 | $-2,642 | $-3,584 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -41 | 0 | 0 | 0 |
| Purchase Sale Intangibles | -26 | -15 | -5 | -15 | -19 |
| Other Investing Activity | -1 | 2 | 0 | -143 | 0 |
| Investing Cash Flow | $-27 | $-54 | $-5 | $-158 | $-19 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 0 | 3,044 | 3,474 | 0 | 1,689 |
| Financing Cash Flow | $0 | $3,044 | $3,474 | $0 | $1,689 |
| Exchange Rate Effect | 9 | 21 | -6 | 11 | 37 |
| Beginning Cash Position | 5,128 | 4,281 | 1,802 | 4,592 | 6,469 |
| End Cash Position | 3,475 | 5,128 | 4,281 | 1,802 | 4,592 |
| Net Cash Flow | $-1,662 | $826 | $2,485 | $-2,800 | $-1,914 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,635 | -2,164 | -984 | -2,642 | -3,584 |
| Capital Expenditure | -26 | -56 | -5 | -15 | -19 |
| Free Cash Flow | -1,661 | -2,220 | -989 | -2,657 | -3,603 |